Original Publication Date: 16 January, 2014
Publication / Source: Biomarkers in Medicine
Authors: Fairleigh Reeves, Nikhil Sapre, Niall Corcoran & Christopher Hovens
In order to individually tailor prostate cancer (PCa) treatment, clinicians need better tools to predict prognosis and treatment response. Given the relationship between angiogenesis and cancer progression, circulating endothelial cells (CECs) and their progenitors have logically been proposed as potential biomarkers. The utility of their baseline levels and kinetics has been investigated for years. However, owing to a lack of standardization and validation of CEC and circulating endothelial progenitors enumeration protocols, results have been inconsistent in prostate and other cancers.